

Yoshihiko Ooka

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4835349/publications.pdf>

Version: 2024-02-01

68
papers

1,606
citations

304368

22
h-index

315357

38
g-index

69
all docs

69
docs citations

69
times ranked

2612
citing authors

#	ARTICLE	IF	CITATIONS
1	Liver diseases in the Asia-Pacific region: a Lancet Gastroenterology & Hepatology Commission. The Lancet Gastroenterology and Hepatology, 2020, 5, 167-228.	3.7	320
2	Very early response of circulating tumourâ€derived DNA in plasma predicts efficacy of nivolumab treatment in patients with nonâ€small cell lung cancer. European Journal of Cancer, 2017, 86, 349-357.	1.3	82
3	Liver function assessment according to the Albuminâ€Bilirubin (ALBI) grade in sorafenib-treated patients with advanced hepatocellular carcinoma. Investigational New Drugs, 2015, 33, 1257-1262.	1.2	75
4	APASL HCV guidelines of virus-eradicated patients by DAA on how to monitor HCC occurrence and HBV reactivation. Hepatology International, 2019, 13, 649-661.	1.9	72
5	Hepatic Arterial Infusion Chemotherapy versus Sorafenib in Patients with Advanced Hepatocellular Carcinoma. Liver Cancer, 2020, 9, 583-595.	4.2	71
6	Disulfiram Eradicates Tumor-Initiating Hepatocellular Carcinoma Cells in ROS-p38 MAPK Pathway-Dependent and -Independent Manners. PLoS ONE, 2014, 9, e84807.	1.1	70
7	A randomized placeboâ€controlled trial of prophylactic dexamethasone for transcatheter arterial chemoembolization. Hepatology, 2018, 67, 575-585.	3.6	57
8	Sequential therapy with sorafenib and regorafenib for advanced hepatocellular carcinoma: a multicenter retrospective study in Japan. Investigational New Drugs, 2020, 38, 172-180.	1.2	57
9	Potential of Lenvatinib for an Expanded Indication from the REFLECT Trial in Patients with Advanced Hepatocellular Carcinoma. Liver Cancer, 2020, 9, 382-396.	4.2	54
10	Characteristics of patients with sorafenib-treated advanced hepatocellular carcinoma eligible for second-line treatment. Investigational New Drugs, 2018, 36, 332-339.	1.2	52
11	Natural history of large regenerative nodules and dysplastic nodules in liver cirrhosis: 28-year follow-up study. Hepatology International, 2015, 9, 330-336.	1.9	44
12	Switching to systemic therapy after locoregional treatment failure: Definition and best timing. Clinical and Molecular Hepatology, 2020, 26, 155-162.	4.5	44
13	Post-progression survival in patients with advanced hepatocellular carcinoma resistant to sorafenib. Investigational New Drugs, 2016, 34, 255-260.	1.2	40
14	Histone lysine methyltransferase G9a is a novel epigenetic target for the treatment of hepatocellular carcinoma. Oncotarget, 2017, 8, 21315-21326.	0.8	39
15	Sustained virologic response achieved after curative treatment of hepatitis <sc>C</sc> virusâ€related hepatocellular carcinoma as an independent prognostic factor. Journal of Gastroenterology and Hepatology (Australia), 2015, 30, 1197-1204.	1.4	36
16	Gadoxetic acid-enhanced MRI compared with CT during angiography in the diagnosis of hepatocellular carcinoma. Magnetic Resonance Imaging, 2013, 31, 748-754.	1.0	34
17	A Prognostic Score for Patients with Intermediate-Stage Hepatocellular Carcinoma Treated with Transarterial Chemoembolization. PLoS ONE, 2015, 10, e0125244.	1.1	34
18	Real-World Experiences with the Combination Treatment of Ledipasvir plus Sofosbuvir for 12 Weeks in HCV Genotype 1-Infected Japanese Patients: Achievement of a Sustained Virological Response in Previous Users of Peginterferon plus Ribavirin with HCV NS3/4A Inhibitors. International Journal of Molecular Sciences, 2017, 18, 906.	1.8	28

#	ARTICLE	IF	CITATIONS
19	Serum fibroblast growth factor 19 serves as a potential novel biomarker for hepatocellular carcinoma. <i>BMC Cancer</i> , 2019, 19, 1088.	1.1	28
20	Posttreatment after Lenvatinib in Patients with Advanced Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2021, 10, 473-484.	4.2	28
21	Evolution of Survival Impact of Molecular Target Agents in Patients with Advanced Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2022, 11, 48-60.	4.2	25
22	Prediction of the very early occurrence of HCC right after DAA therapy for HCV infection. <i>Hepatology International</i> , 2018, 12, 523-530.	1.9	24
23	Effect of Previous Interferon-based Therapy on Recurrence after Curative Treatment of Hepatitis C Virus-related Hepatocellular Carcinoma. <i>International Journal of Medical Sciences</i> , 2014, 11, 707-712.	1.1	21
24	Efficacy of transarterial chemoembolization targeting portal vein tumor thrombus in patients with hepatocellular carcinoma. <i>Anticancer Research</i> , 2014, 34, 4231-7.	0.5	21
25	The impact of FGF19/FGFR4 signaling inhibition in antitumor activity of multi-kinase inhibitors in hepatocellular carcinoma. <i>Scientific Reports</i> , 2021, 11, 5303.	1.6	20
26	Fatal Diaphragmatic Hernia following Radiofrequency Ablation for Hepatocellular Carcinoma: A Case Report and Literature Review. <i>Case Reports in Oncology</i> , 2015, 8, 238-245.	0.3	18
27	Presence of non-enhancing hypovascular hypointense nodules on Gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging in patients with hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 908-915.	1.4	15
28	Impact of Radiofrequency Ablation-Induced Glisson's Capsule-Associated Complications in Patients with Hepatocellular Carcinoma. <i>PLoS ONE</i> , 2017, 12, e0170153.	1.1	15
29	Clinical outcomes of endoscopic ultrasound-guided ethanol injection for hepatocellular carcinoma in the caudate lobe. <i>Endoscopy International Open</i> , 2016, 04, E1111-E1115.	0.9	12
30	Biological features and biomarkers in hepatocellular carcinoma. <i>World Journal of Hepatology</i> , 2015, 7, 2020.	0.8	12
31	A phase I/II study of S-1 with sorafenib in patients with advanced hepatocellular carcinoma. <i>Investigational New Drugs</i> , 2014, 32, 723-728.	1.2	11
32	Treatment of Real-World HCV Genotype 2-Infected Japanese Patients with Sofosbuvir plus Ribavirin. <i>Biology</i> , 2017, 6, 30.	1.3	11
33	Successful Interventional Treatment for Arterioportal Fistula Caused by Radiofrequency Ablation for Hepatocellular Carcinoma. <i>Case Reports in Oncology</i> , 2014, 7, 833-839.	0.3	10
34	Analyses of Intermediate-Stage Hepatocellular Carcinoma Patients Receiving Transarterial Chemoembolization prior to Designing Clinical Trials. <i>Liver Cancer</i> , 2020, 9, 596-612.	4.2	10
35	Interferon-free treatment for patients with chronic hepatitis C and autoimmune liver disease: higher SVR rates with special precautions for deterioration of autoimmune hepatitis. <i>Oncotarget</i> , 2018, 9, 11631-11637.	0.8	10
36	IFNL4 ss469415590 Variant Is Associated with Treatment Response in Japanese HCV Genotype 1 Infected Individuals Treated with IFN-Including Regimens. <i>International Journal of Hepatology</i> , 2014, 2014, 1-6.	0.4	9

#	ARTICLE	IF	CITATIONS
37	Initial response to sorafenib by using enhancement criteria in patients with hepatocellular carcinoma. <i>Hepatology International</i> , 2013, 7, 703-713.	1.9	7
38	Analysis of Sorafenib Outcome: Focusing on the Clinical Course in Patients with Hepatocellular Carcinoma. <i>PLoS ONE</i> , 2016, 11, e0161303.	1.1	7
39	Prognostic Significance of Concurrent Hypovascular and Hypervascular Nodules in Patients with Hepatocellular Carcinoma. <i>PLoS ONE</i> , 2016, 11, e0163119.	1.1	6
40	Risk factors of ineffective drainage in uncovered self-expandable metal stenting for unresectable malignant hilar biliary strictures. <i>Oncotarget</i> , 2018, 9, 28185-28194.	0.8	6
41	Transarterial chemoembolization as a substitute to radiofrequency ablation for treating Barcelona Clinic Liver Cancer stage 0/A hepatocellular carcinoma. <i>Oncotarget</i> , 2018, 9, 21560-21568.	0.8	6
42	Transarterial chemoembolization with miriplatin plus epirubicin in patients with hepatocellular carcinoma. <i>Anticancer Research</i> , 2015, 35, 549-54.	0.5	6
43	Intracranial Metastasis in a Patient with Hepatocellular Carcinoma and Gastric Cancer. <i>Case Reports in Oncology</i> , 2014, 7, 199-203.	0.3	5
44	Genome-Wide Mapping of Bivalent Histone Modifications in Hepatic Stem/Progenitor Cells. <i>Stem Cells International</i> , 2019, 2019, 1-10.	1.2	5
45	Long-term administration of Tolvaptan to patients with decompensated cirrhosis. <i>International Journal of Medical Sciences</i> , 2020, 17, 874-880.	1.1	5
46	Successful retreatment with sofosbuvir plus ledipasvir for cirrhotic patients with hepatitis C virus genotype 1b, who discontinued the prior treatment with asunaprevir plus daclatasvir: A case series and review of the literature. <i>Oncotarget</i> , 2018, 9, 5509-5513.	0.8	5
47	Successful retreatment with grazoprevir and elbasvir for patients infected with hepatitis C virus genotype 1b, who discontinued prior treatment with NS5A inhibitor-including regimens due to adverse events. <i>Oncotarget</i> , 2018, 9, 16263-16270.	0.8	5
48	Partial Splenic Embolization with Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma Accompanied by Thrombocytopenia. <i>BioMed Research International</i> , 2014, 2014, 1-6.	0.9	4
49	Impact of acute decompensation on the prognosis of patients with hepatocellular carcinoma. <i>PLoS ONE</i> , 2022, 17, e0261619.	1.1	4
50	Tolvaptan treatment for patients with decompensated cirrhosis and advanced hepatocellular carcinoma. <i>Hepatology Research</i> , 2015, 45, E161-2.	1.8	3
51	Henoch-Schönlein Purpura Complicated by Hepatocellular Carcinoma. <i>Internal Medicine</i> , 2017, 56, 3041-3045.	0.3	3
52	Transcatheter arterial infusion for advanced hepatocellular carcinoma: Who are candidates?. <i>World Journal of Gastroenterology</i> , 2015, 21, 8888.	1.4	3
53	Dexamethasone for the prevention of transcatheter arterial chemoembolization-induced fever, nausea, vomiting, and anorexia in patients with hepatocellular carcinoma: A randomized, double-blind, placebo-controlled trial. <i>Journal of Clinical Oncology</i> , 2016, 34, 4071-4071.	0.8	3
54	A case of hepatocellular carcinoma with spontaneous regression of a tumor thrombus invading the main portal trunk. <i>Acta Hepatologica Japonica</i> , 2016, 57, 178-185.	0.0	2

#	ARTICLE	IF	CITATIONS
55	Suspected heparin-induced thrombocytopenia in patients with advanced hepatocellular carcinoma following hepatic arterial infusion chemotherapy. <i>Acta Hepatologica Japonica</i> , 2017, 58, 647-653.	0.0	2
56	A case of hepatocellular carcinoma with disappearance of lymph node metastasis after sorafenib administration. <i>Acta Hepatologica Japonica</i> , 2015, 56, 469-476.	0.0	1
57	Two patients with hepatic mucosa-associated lymphoid tissue lymphoma resembling hypervascular hepatocellular carcinoma. <i>Acta Hepatologica Japonica</i> , 2015, 56, 536-539.	0.0	1
58	Successful treatment of three elderly patients aged 80-90 years with hepatocellular carcinoma. <i>Acta Hepatologica Japonica</i> , 2015, 56, 628-631.	0.0	1
59	Successful treatment of two patients with hepatocellular carcinoma exhibiting severe pancytopenia caused by aplastic anemia. <i>Acta Hepatologica Japonica</i> , 2016, 57, 557-560.	0.0	1
60	A case of arteriovenous fistula due to a ruptured hepatic aneurysm during sorafenib therapy for hepatocellular carcinoma. <i>Acta Hepatologica Japonica</i> , 2017, 58, 605-610.	0.0	1
61	Respiratory-synchronized digital subtraction angiography based on a respiratory phase matching method. <i>Signal, Image and Video Processing</i> , 2018, 12, 539-547.	1.7	1
62	Weight-based dosing of lenvatinib for advanced hepatocellular carcinoma. <i>Hepatobiliary Surgery and Nutrition</i> , 2020, 9, 253-254.	0.7	1
63	A case of hepatocellular carcinoma followed by asynchronous metastasis to the lung and thoracic spine following radical ablation treatment. <i>Acta Hepatologica Japonica</i> , 2021, 62, 25-32.	0.0	1
64	Vascular Roadmap Generation by Registration and Blending of Multiple Enhanced X-ray Angiograms. <i>IEEE Access</i> , 2021, 9, 36356-36367.	2.6	1
65	Three hepatocellular carcinoma patients with pleural effusion successfully treated by pleurodesis with a view to palliative medicine. <i>Acta Hepatologica Japonica</i> , 2015, 56, 213-216.	0.0	0
66	Successful Treatment of Hepatocellular Carcinoma Complicated by Fanconi Anemia. <i>Case Reports in Gastroenterology</i> , 2017, 11, 29-35.	0.3	0
67	Hepatocellular carcinoma complicated by acute promyelocytic leukemia: a case report. <i>Acta Hepatologica Japonica</i> , 2017, 58, 176-182.	0.0	0
68	A phase I/II study of capecitabine combined with peginterferon alfa-2a in sorafenib-refractory advanced hepatocellular carcinoma patients. <i>Journal of Clinical Oncology</i> , 2014, 32, 346-346.	0.8	0